TY  - JOUR

T1  - Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

JO  - Journal of Clinical Oncology

PY  - 2013/06/20

AU  - James ND

AU  - Pirrie S

AU  - Barton D

AU  - Brown JE

AU  - Billingham L

AU  - Collins SI

AU  - Daunton A

AU  - Birtle AJ

AU  - Chakraborti PR

AU  - Ford D

AU  - Hussain SA et al

ED  - 

DO  - DOI: 10.1200/jco.2013.31.18_suppl.lba5000

PB  - American Society of Clinical Oncology (ASCO)

VL  - 31

IS  - 18_suppl

SP  - LBA5000

EP  - LBA5000

Y2  - 2024/12/22

ER  -